|
|
|
|
|
|
| Staffan Gestrelius and Jerker Ringstrom of Capish, a solution provider at the marcus evans Evolution Summit 2012 in North America and Evolution Summit 2012 in Europe, on unlocking the data of clinical trials for more profitable clinical development. |
NEW YORK, N.Y., Aug 6, 2012 - (ACN Newswire) - Scientists must unlock and analyze data throughout the clinical trial, according to Staffan Gestrelius, President and Chief Executive Officer and Jerker Ringstrom, Head of Business Development, Capish. From a solution provider company at the marcus evans Evolution Summit 2012, in North America and the Evolution Summit 2012 in Europe, Gestrelius and Ringstrom discuss how knowledge directly impacts the profitability of clinical development.
- What role can Business Intelligence tools play in clinical development?
Staffan Gestrelius: Scientists need to probe and analyze data the way the financial sector does. To make better decisions and learn more about their compounds and patients, they must unlock data throughout the study and not just at the end. This will become even more important with personalized medicine.
- How can clinical data become a knowledge asset?
Jerker Ringstrom: One of the most important words in this space is "knowledge". To turn data into a knowledge asset, it must be put into perspective. Scientists need constant feedback when deciding whether to continue with a program or to make amendments.
If you look at a clinical trial protocol, it usually mirrors the situation of the study six to eight months before it ended. This means there was time to make valuable changes to the design and improve the quality of the trial.
- How could this enhance safety?
Staffan Gestrelius: If you have a system that continuously watches over patients and gives you access to graphs and statistics, you can keep track of adverse events and drug associated adverse effects. The earlier this is done, the better.
Jerker Ringstrom: This also helps pharmaceutical companies be patient centric. When you develop a new drug, you need to come up with a diagnostic tool. The patient plays a more central role than before, as the diagnosis will be the torch through the darkness. I emphasize darkness, because when you focus on means and standard deviations then all of a sudden you have to focus on the patient and what genetic patterns or biomarkers he reacts to, this will be an important turning point in drug development.
- Can it help scientists be more innovative? How?
Jerker Ringstrom: Scientists can get new ideas for indications by better analyzing data. More drugs today are being used in new formulations and for new indications, but finding these new indications is proving to be challenging.
- How is this approach more profitable?
Staffan Gestrelius: This will be a knowledge game. It will become crucial to know everything about a specific drug. This approach is more profitable because people are not willing to pay for a drug that only has a 50 per cent chance of curing them. The reason why many companies are troubled today is because they do not have good enough treatments.
Knowledge directly impacts profitability. Pharmaceutical companies should focus more on knowledge than on showing that the drug is not dangerous, simply to get it approved by the FDA. This will not be enough.
For more information please send an email to info@marcusevanscy.com or visit the event websites below:
Evolution Summit 2012 - North America: www.evolutionsummit.com/StaffanGestreliusandJerkerRingstromInterview
Evolution Summit 2012 - Europe:
www.evolution-summit.com/StaffanGestreliusandJerkerRingstromInterview
marcus evans group - life sciences / pharma sector portal - http://bit.ly/HEbwqQ
The Pharma Network - marcus evans Summits group delivers peer-to-peer information on strategic matters, professional trends and breakthrough innovations.
- LinkedIn: www.linkedin.com/groups?gid=3529112&trk=myg_ugrp_ovr
- YouTube: www.youtube.com/user/MarcusEvansPharma
- Twitter: www.twitter.com/meSummitsPharma
- SlideShare: www.slideshare.net/MarcusEvansPharma
Please note that the Summit is a closed business event and the number of participants strictly limited.
About Capish
Capish is a Swedish Knowledge Management Service Organisation founded in 2001. We can give non-data literate experts immediate access to all clinical and non-clinical information through easy-to-use web-based interactive graphical interfaces for searching and also interactive statistical tools for analyses. Capish will shortly be available for prospective trials. www.capishknowledge.com.
Contact:
Sarin Kouyoumdjian-Gurunlian
Press Manager, marcus evans, Summits Division
Tel: + 357 22 849 313
Email: press@marcusevanscy.com
Topic: Research / Industry Report
Source: marcus evans Summits
Sectors: Daily Finance, Daily News
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
